2018-004623-36: MEGALiT - a study in which the effect of established cancer drugs is investigated on new cancers that have a specific molecular signature MEGALiT - en studie där effekten av etablerade cancerläkemedel undersöks på nya cancersjukdomar som har en specifik molekylär signatur |
|
|
| Not yet recruiting | 2 | 154 | Europe | Tecentriq, Cotellic, Zejula, Everolimus, RO5514041/F04, Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Tecentriq, Cotellic, Zejula | Uppsala University Hospital, Roche AB | In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 1 | 1200 | Europe, Canada, Japan, US, RoW | Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus | Amgen | Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation | 12/26 | 12/27 | | |